Oxford BioMedica and Sigma-Aldrich Issue Joint Licence for LentiVector^® Technology to GlaxoSmithKline

Oxford BioMedica Expands Licensing Agreement for LentiVector^® Technology with Major Pharmaceutical Company

Oxford BioMedica's Trovax® Receives Positive Recommendation for Orphan Drug Designation in Renal Cancer from EMEA

Oxford BioMedica Presents Encouraging Preclinical Efficacy Data with ProSavin^® in Parkinson's Disease

Oxford BioMedica Reports Further Encouraging Phase II Results with Trovax^® in Renal and Prostate Cancer
View abstract (108kb)

Oxford BioMedica Commences Phase III Trial of TroVax^® in Renal Cancer

Oxford BioMedica Presents Encouraging Immunological Data From Six Phase Il Trials of TroVax^® in Various Cancers View Poster (871kb)

Oxford BioMedica Expands Its Ocular Programme Through Collaboration and Investment Led by the Foundation Fighting Blindness

Oxford BioMedica Plc Interim Results for the six months ended 30 June 2006

Southwest Oncology Group to Start Phase II Trial of Oxford BioMedica's TroVax in Breast Cancer

Leading US clinician to present on Oxford BioMedica's TroVax^® at cancer conference

Oxford BioMedica Notice of Interim Results for the Six Months Ended 30 June 2006

Update and Clarification on TroVax

Oxford BioMedica Receives Notice of Allowance for Key US Patent Covering Parkinson's Disease Product, Prosavin^®

Oxford BioMedica to Present at Piper Jaffray Health Care Conference

Oxford BioMedica and Partner Sigma-Aldrich Pursue Protection of RNAi-Related IP Against Open Biosystems

Oxford BioMedica Reports New Encouraging Phase II Results with TroVax^® and Progress in the Development Plan
View Abstracts  (87kb) View Posters (296kb)